Global burden of hepatitis B virus: current status, missed opportunities and a call for action
Chronic hepatitis B virus (HBV) infection affects about 296 million people worldwide and is
the leading aetiology of cirrhosis and liver cancer globally. Major medical complications also …
the leading aetiology of cirrhosis and liver cancer globally. Major medical complications also …
[HTML][HTML] Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection
CL Lin, JH Kao - Clinical and Molecular Hepatology, 2023 - ncbi.nlm.nih.gov
Hepatitis B virus (HBV) is responsible for more than 50% of hepatocellular carcinoma (HCC)
in HBV hyperendemic areas, such as the Asia-Pacific region. Several hepatitis B viral factors …
in HBV hyperendemic areas, such as the Asia-Pacific region. Several hepatitis B viral factors …
Inhibition of viral replication reduces transcriptionally active distinct hepatitis B virus integrations with implications on host gene dysregulation
Background & aims Hepatocellular carcinogenesis of hepatitis B virus (HBV) infection may
arise from integration of viral DNA into the host genome. We aimed to gauge the effect of …
arise from integration of viral DNA into the host genome. We aimed to gauge the effect of …
Current best practice in hepatitis B management and understanding long-term prospects for cure
The hepatitis B virus (HBV) is a major cause of cirrhosis and hepatocellular carcinoma
worldwide. Despite an effective vaccine, the prevalence of chronic infection remains high …
worldwide. Despite an effective vaccine, the prevalence of chronic infection remains high …
Evidence for benefits of early treatment initiation for chronic hepatitis B
Chronic hepatitis B (CHB) is the most common cause of hepatocellular carcinoma (HCC)
worldwide. Antiviral treatment reduces the risk of HCC and mortality; nonetheless, globally in …
worldwide. Antiviral treatment reduces the risk of HCC and mortality; nonetheless, globally in …
Hepatitis B core-related antigen stratifies the risk of liver cancer in HBeAg-negative patients with indeterminate phase
METHODS: Two retrospective cohorts enrolling HBeAg-negative, treatment-naïve CHB
patients without cirrhosis were constructed (N= 2,150 in Taiwanese discovery cohort and N …
patients without cirrhosis were constructed (N= 2,150 in Taiwanese discovery cohort and N …
Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-positive patients
Methods: Using a multinational cohort from Korea, Hong Kong, and Taiwan involving 7,545
HBeAg-positive, non-cirrhotic, adult CHB patients who started entecavir or tenofovir …
HBeAg-positive, non-cirrhotic, adult CHB patients who started entecavir or tenofovir …
[HTML][HTML] Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
Background & Aims Antiviral therapy may attenuate the risk of hepatocellular carcinoma
(HCC) in patients with chronic hepatitis B (CHB). We aimed to explore how tenofovir …
(HCC) in patients with chronic hepatitis B (CHB). We aimed to explore how tenofovir …
[HTML][HTML] HBcrAg-based risk score performs better than the HBV DNA-based scores for HCC prediction in grey zone patients who are HBeAg-negative
Abstract Background & Aims Risk scores have been designed to predict the development of
hepatocellular carcinoma (HCC) in treatment-naive patients with chronic hepatitis B (CHB) …
hepatocellular carcinoma (HCC) in treatment-naive patients with chronic hepatitis B (CHB) …
Clinical and histological features of patients with chronic hepatitis B virus infection in the grey zone
QY Gan, JX Wang, F Qian, YL Wang… - Journal of Viral …, 2023 - Wiley Online Library
Chronic HBV infection patients who do not conform to any of the usual immune states are
regarded as 'grey zone'patients. We aimed to investigate the proportion of chronic HBV …
regarded as 'grey zone'patients. We aimed to investigate the proportion of chronic HBV …